Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
41 hedge funds and large institutions have $173M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2017 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 5 closing their positions.
360% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 5
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
78% more funds holding
Funds holding: 23 → 41 (+18)
7% less capital invested
Capital invested by funds: $187M → $173M (-$14M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$11.9M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$6.56M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$6.06M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$5.56M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$5.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$11.9M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$5.12M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.77M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.76M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.68M |
NBRV Hedge Fund Activity: Q3 2017 in Review
41 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q3 2017, worth a combined $173M — down 7.5% from $187M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new NBRV positions and 5 closed out — a net gain of 18 holders — while 11 added to existing stakes and 4 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $11.9M. The largest seller was Omega Fund Management, exiting entirely with an estimated $11.9M sold.
- 41 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q3 2017, up from 23 in Q2 2017.
- Funds reported $173M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q3 2017, down 7.5% quarter-over-quarter.
- 23 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q3 2017 and 5 closed out, a net change of +18 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q3 2017 was Morgan Stanley, an estimated $11.9M added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q3 2017 was Omega Fund Management, an estimated $11.9M sold.
Based on aggregated 13F filings for Q3 2017.